Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

193.81 -7.37 (-3.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
57 58 Next >
News headline image
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock ↗
Cassava had $168.4 million of cash at the end of June after losing $28.7 million during the second quarter of 2023. SAVA stock is up 5% 
Via InvestorPlace
News headline image
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month? ↗
The pharmaceutical company's growth prospects have taken a big hit. 
Via The Motley Fool
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today ↗
 
Via Benzinga
News headline image
Looking Into Biogen's Recent Short Interest ↗
 
Via Benzinga
News headline image
Is Sage Therapeutics a Contrarian Buy? ↗
A regulatory setback weighed heavily on the drugmaker's shares Monday. 
Via The Motley Fool
News headline image
Biogen Unusual Options Activity For August 02 ↗
 
Via Benzinga
News headline image
Why Shares of Sage Therapeutics Slumped This Week ↗
The company got bad news from the FDA and saw increased losses. 
Via The Motley Fool
News headline image
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around? ↗
The company's rare disease portfolio may soon get an upgrade. 
Via The Motley Fool
News headline image
With an Acquisition on the Way, Is Biogen Stock a Buy? ↗
Can the biotech finally get back in the good graces of investors? 
Via The Motley Fool
News headline image
Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy? ↗
Lilly shares surged 15% in one day to a record high. Here's what you should know. 
Via Investor's Business Daily
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market... 
Via Benzinga
News headline image
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead ↗
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD) but issued a Complete Response Letter 
Via Benzinga
News headline image
Dow Rises Over 300 Points To Start The Week ↗
The Dow Jones Industrial Average was last seen up 308 points, as the blue-chip index looks to start the week on a high note following its recent losses. 
Via Talk Markets
News headline image
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says ↗
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
Via Benzinga
News headline image
PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug ↗
The company gained approval for the first oral treatment for postpartum depression. 
Via Investor's Business Daily
News headline image
FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another ↗
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with  
Via Benzinga
News headline image
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
From Biogen Inc.
Via GlobeNewswire
News headline image
3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now ↗
Biotech stocks can be a lucrative investment opportunity, these three biotech stocks to buy now are among analyst favorites. 
Via InvestorPlace
News headline image
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points ↗
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now. 
Via InvestorPlace
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Talaris Therapeutics, Inc. (Nasdaq - TALS), Inpixon® (Nasdaq - INPX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know. ↗
Biogen also recently announced a plan to cut costs and focus investment on high-growth areas. 
Via The Motley Fool
News headline image
Rising Stars, Falling Trends: July's Industry ETF Winners And Losers ↗
 
Via Benzinga
News headline image
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen ↗
By 2024, their medicines will likely be competing on the market, and one might win. 
Via The Motley Fool
News headline image
Could This Stock Be the Next Biotech Buyout? ↗
A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next. 
Via The Motley Fool
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.